Live from the NIH registry
Studies recruiting near Naperville right now
Top 25 of 2,351 recruiting studies, sorted by proximity — each links to its official registry page
Combining MyoCI With Memory Reactivation to Improve Motor Recovery After Stroke
Stroke
N/A
Interventional 70 participants sought
Northwestern University — Chicago, Illinois (27.5 mi)
· Sponsor: Northwestern University
CLOZAPINE Response in Biotype-1
Schizophrenia, Schizoaffective Disorder
Phase 4
Interventional 524 participants sought
University of Chicago — Chicago, Illinois (27.5 mi)
· Sponsor: University of Texas Southwestern Medical Center
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 2
Interventional 120 participants sought
Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois (27.5 mi)
· Sponsor: Nationwide Children's Hospital
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Advocate Children's Hospital-Oak Lawn — Oak Lawn, Illinois (21.2 mi)
· Sponsor: National Cancer Institute (NCI)
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Gonorrhea, Chlamydia
Phase 4
Interventional 760 participants sought
University Illinois Chicago — Chicago, Illinois (27.5 mi)
· Sponsor: Westat
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Phase 2
Interventional 594 participants sought
University of Chicago Medical Center ( Site 0126) — Chicago, Illinois (27.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Northwestern University — Chicago, Illinois (27.5 mi)
· Sponsor: Medtronic MiniMed, Inc.
Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts
Warts, Verruca (Warts)
Phase 2
Interventional 55 participants sought
Rush University Medical Center — Chicago, Illinois (27.5 mi)
· Sponsor: Rush University Medical Center
One-Time DNA Study for Vasculitis
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis
N/A
Observational 1,000 participants sought
Northwestern University — Chicago, Illinois (27.5 mi)
· Sponsor: University of Pennsylvania
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Cancer Treatment Centers of America-Chicago — Chicago, Illinois (27.5 mi)
· Sponsor: American Society of Clinical Oncology
Forceps vs. Snare IVC Filter Removal
DVT
N/A
Interventional 100 participants sought
UChicago Medicine — Chicago, Illinois (27.5 mi)
· Sponsor: University of Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Prostate Cancer, Prostate Adenocarcinoma
Phase 2
Interventional 90 participants sought
University of Chicago Comprehensive Cancer Center — Chicago, Illinois (27.5 mi)
· Sponsor: University of Chicago
Understanding How Powered Componentry Impacts K2-Level Transfemoral Amputee Gait
Amputation, Amputation, Traumatic
N/A
Interventional 20 participants sought
Shirley Ryan AbilityLab — Chicago, Illinois (27.5 mi)
· Sponsor: Shirley Ryan AbilityLab
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
Overactive Bladder (OAB), Urinary Urgency
N/A
Interventional 596 participants sought
University of Chicago — Chicago, Illinois (27.5 mi)
· Sponsor: Medstar Health Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Ulcerative Colitis
Phase 2
Interventional 224 participants sought
University of Chicago Medical Center — Chicago, Illinois (27.5 mi)
· Sponsor: Genentech, Inc.
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Rush University Medical Center — Chicago, Illinois (27.5 mi)
· Sponsor: Relay Therapeutics, Inc.
Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement
Healthy Adult
N/A
Interventional 34 participants sought
Biofortis Clinical Research — Addison, Illinois (15.6 mi)
· Sponsor: Shaklee Corporation
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
Spinal Cord Injury, Pressure Injury
N/A
Interventional 808 participants sought
Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois (18.3 mi)
· Sponsor: VA Office of Research and Development
Treatment of Moderate to Severe Refractory Crohn's Disease
Crohns Disease
Phase 1, Phase 2
Interventional 39 participants sought
Northwestern — Chicago, Illinois (27.5 mi)
· Sponsor: Tr1X, Inc.
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
Illinois Cancer Specialists — Arlington Heights, Illinois (25.4 mi)
· Sponsor: SCRI Development Innovations, LLC
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Acute Respiratory Failure
N/A
Observational 2,092 participants sought
Rush University Medical Center — Chicago, Illinois (27.5 mi)
· Sponsor: Brian Driver
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Arlington Heights, Illinois (25.4 mi)
· Sponsor: AstraZeneca
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Cancer, Bladder Cancer
Phase 2, Phase 3
Interventional 630 participants sought
Research Site — Niles, Illinois (26.4 mi)
· Sponsor: Daiichi Sankyo
Study of the Progression of Chronic Cardiovascular Conditions
Cardiovascular Disease (CVD), Heart Failure
N/A
Observational 5,000 participants sought
Prolaio — Chicago, Illinois (27.5 mi)
· Sponsor: Prolaio
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Phase 3
Interventional 348 participants sought
Psychiatric Medicine Associates LLC — Skokie, Illinois (29.7 mi)
· Sponsor: Janssen Research & Development, LLC